Blog Exposure - Blueprint Medicines Signed Collaboration Deal with CStone Pharma to Develop and Commercialize Avapritinib, BLU-554, and BLU-667 in Greater China

Stock Monitor: Verona Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / June 6, 2018 / If you want access to our free research report on Blueprint Medicines Corp. (NASDAQ: BPMC), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BPMC as the Company's latest news hit the wire. On June 04, 2018, the Company announced that it has signed an exclusive collaboration and license deal with China based CStone Pharmaceuticals for the development and commercialization of Blueprint Medicines' avapritinib, BLU-554, and BLU-667 in Mainland China, Hong Kong, Macau, and Taiwan, either as monotherapies or combination therapies. Blueprint Medicines will retain all rights to the licensed products in the rest of the world. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Verona Pharma PLC (NASDAQ: VRNA), which also belongs to the Healthcare sector as the Company Blueprint Medicines. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=VRNA

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Blueprint Medicines most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=BPMC

Terms of the Collaboration Deal

• CStone Pharma will make an upfront cash payment of $40 million to Blueprint Medicines, along with approximately $346 million in potential milestone payments, including $118.5 million related to development and regulatory milestones and $227.5 million related to sales-based milestones.

• Additionally, CStone Pharma will be obligated to pay Blueprint Medicines tiered percentage royalties on a licensed product-by-licensed product basis ranging from the mid-teens to low twenties on annual net sales of each licensed product in the territory, subject to adjustment in specified circumstances.

• As per the agreement terms, CStone Pharma will be responsible for conducting all development and commercialization activities in the territory related to the licensed products.

• CStone Pharma will also be responsible for costs related to the development of the licensed products in the territory, other than specified costs related to the development of BLU-554 as a combination therapy in the territory that will be shared by the companies.

Companies to Initiate a Proof-of-Concept Clinical Trial in China Evaluating BLU-554 in Combination with CS1001 for HCC Treatment

The collaboration strengthens CStone Pharma's portfolio with exclusive rights in the territory to three clinical-stage targeted therapies and expands Blueprint Medicines' global efforts to address patient populations with high unmet needs. CStone Pharma will leverage its regulatory expertise and broad local network for commercializing the licensed products in the territory either as monotherapies or combination therapies. The companies plan to initiate a proof-of-concept clinical trial in China evaluating BLU-554 in combination with CS1001, a clinical-stage anti-programmed death ligand-1 (PD-L1) immunotherapy being developed by CStone Pharma, as a first-line therapy for patients with hepatocellular carcinoma (HCC).

CStone Pharma's Rich Pipeline of Investigational Cancer Medicines Enables Exploration of Combination Treatment Approaches

Commenting on the collaboration, Frank Jiang, CEO of CStone Pharma, stated that based on the compelling clinical data reported to date, CStone Pharma believes Blueprint Medicines' targeted therapies- avapritinib, BLU-554 and BLU-667 hold promise for dramatically altering the treatment landscape for patients in China with gastrointestinal stromal tumors, hepatocellular carcinoma, non-small cell lung cancer and other cancers.

Frank added that CStone Pharma's rich pipeline of investigational cancer medicines enables exploration of combination treatment approaches with the potential to further improve patient outcomes worldwide.

About Avapritinib, BLU-554, and BLU-667

Avapritinib is an orally available, potent and highly selective inhibitor of KIT and PDGFRα. Preclinical data have shown that avapritinib is active across a broad spectrum of KIT and PDGFRα mutations, including KIT D816V, PDGFRα D842V and KIT exon 17 mutations, for which there are limited or no effective treatment options. Blueprint Medicines is initially developing avapritinib, an investigational medicine, for the treatment of patients with advanced gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis.

BLU-554 is an orally available, potent, irreversible inhibitor of FGFR4. BLU-554 was specifically designed by Blueprint Medicines to inhibit FGFR4 with exquisite selectivity, thereby sparing the paralogs FGFR1, FGFR2, and FGFR3. Blueprint Medicines is developing BLU-554, an investigational medicine, for the treatment of patients with FGFR4-activated HCC.

BLU-667 is an orally available, potent and highly selective inhibitor designed to target RET fusions, mutations and predicted resistance mutations. Blueprint Medicines is developing BLU-667, an investigational medicine, for the treatment of patients with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer and other solid tumors. BLU-667 was discovered by Blueprint Medicine's research team leveraging its proprietary compound library.

About CStone Pharmaceuticals

Established in 2016, CStone Pharma is a Shanghai-based biopharmaceutical company devoted to the development of a new generation of innovative drugs. With its broad immuno-oncology pipeline, CStone Pharma is pursuing a development strategy focusing on combination therapy.

About Blueprint Medicines Corp.

Founded in 2011 and headquartered in Cambridge, Massachusetts, Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases.

Stock Performance Snapshot

June 05, 2018 - At Tuesday's closing bell, Blueprint Medicines' stock fell 1.79%, ending the trading session at $75.30.

Volume traded for the day: 895.63 thousand shares, which was above the 3-month average volume of 460.17 thousand shares.

Stock performance in the previous six-month period – up 3.41%; and past twelve-month period – up 103.79%

After yesterday's close, Blueprint Medicines' market cap was at $3.29 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors